Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Marina Maher Communications

- PMLiVE

Making mobile health technology work

Augmenting organic life with artificial technology is gaining ground in healthcare

Boehringer trials digital diabetes programme

Will study effect of self-management technology on clinical care

- PMLiVE

Lilly/ Boehringer’s Lantus biosimilar accepted for EMA review

Moves pharma companies’ version of Sanofi's blockbuster insulin a step closer to approval

- PMLiVE

The rise of chronic disease in BRIC markets

Changing disease patterns in the BRIC nations are providing new opportunities for growth

Sanofi reception

Sanofi wins Japanese approval for diabetes drug Lyxumia

Becomes first treatment of its class licensed in combination with basal insulin

- PMLiVE

ADA: Lilly’s once-weekly diabetes drug bests Januvia and Byetta

Late-stage trials of dulaglutide show superiority over established brands

- PMLiVE

Merck wins injunction against Januvia generics in India

Court blocks Aprica from launching copycat diabetes drug

- PMLiVE

ADA: Sanofi eyes 2014 submissions for Lantus successor

Releases first phase III data for U300 formulation of insulin glargine

- PMLiVE

ADA: Novo Nordisk steps up Lantus challenge with new Tresiba data

But still faces at least a three-year wait for US approval

- PMLiVE

ADA: Boehringer/ Lilly’s empagliflozin shows blood glucose benefits

Phase III results for diabetes candidate also indicate significant weight loss

- PMLiVE

Setback for AZ and BMS as Onglyza flunks cardiovascular trial

Diabetes drug fails to show benefit over placebo

- PMLiVE

US charity calls for release of diabetes drug data

American Diabetes Association demands review of incretin-based medicines linked to pancreatic cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links